These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20410614)

  • 1. Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.
    Hanamura M; Iwamoto T; Soga N; Sugimura Y; Okuda M
    Biol Pharm Bull; 2010; 33(4):721-4. PubMed ID: 20410614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the risk factors associated with hypocalcemia induced by denosumab.
    Okada N; Kawazoe K; Teraoka K; Kujime T; Abe M; Shinohara Y; Minakuchi K
    Biol Pharm Bull; 2013; 36(10):1622-6. PubMed ID: 23934346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A
    J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
    [No Abstract]   [Full Text] [Related]  

  • 4. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL; Wu S; Arlen PM; Dahut WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
    Ho JW; Sundar S
    Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101
    [No Abstract]   [Full Text] [Related]  

  • 6. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
    Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
    Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level.
    Epperla N; Pathak R
    WMJ; 2015 Aug; 114(4):163-6; quiz 167. PubMed ID: 26436186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.
    Berruti A; Cook R; Saad F; Buttigliero C; Lipton A; Tampellini M; Lee KA; Coleman RE; Smith MR
    Oncologist; 2012; 17(5):645-52. PubMed ID: 22523198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
    Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
    Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
    Nasser SM; Sahal A; Hamad A; Elazzazy S
    J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
    Patel K; Brahmbhatt V; Ramu V
    Tenn Med; 2005 Feb; 98(2):83-5, 89. PubMed ID: 15779196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid treatment at home: safety data from an observational prospective trial.
    Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
    J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
    Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
    Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibition of RANK ligand to treat bone metastases].
    Body JJ
    Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
    Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
    Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
    Denham JW; Nowitz M; Joseph D; Duchesne G; Spry NA; Lamb DS; Matthews J; Turner S; Atkinson C; Tai KH; Gogna NK; Kenny L; Diamond T; Smart R; Rowan D; Moscato P; Vimieiro R; Woodfield R; Lynch K; Delahunt B; Murray J; D'Este C; McElduff P; Steigler A; Kautto A; Ball J
    BJU Int; 2014 Sep; 114(3):344-53. PubMed ID: 24512527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases.
    Lechner B; DeAngelis C; Jamal N; Emmenegger U; Pulenzas N; Giotis A; Sheehan P; Tsao M; Bedard G; Chow E
    Support Care Cancer; 2014 Jul; 22(7):1765-71. PubMed ID: 24515277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
    Paparella S; Finkelberg E; Varisco D; Tondelli E; Rocco F
    Urologia; 2011; 78(4):300-4. PubMed ID: 22139807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia.
    Cure E; Yuce S; Cure MC
    Minerva Endocrinol; 2013 Jun; 38(2):217-8. PubMed ID: 23732377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.